Abstract Library

#4631 Correlations between dosimetry and imaging in patients with neuroendocrine tumour treated with 177Lu-DOTATATE

Introduction: Tumour dose may be an important predictor of clinical response, but estimation of a clinically relevant tumour-absorbed dose without high risk of toxicity is challenging.

Conference:

Presenting Author: Gomez Sanchez D

Authors: Gomez Sanchez D, Ribelles M, Fernandez Iglesias A, Paruta Araez L, Mata E,

Keywords: dosimetry, 177Lu-DOTATATE,

#4578 Dissecting the role of collagen quantitation via tissue-tethered digital analysis in small bowel neuroendocrine tumours and related mesenteric tumour deposits

Introduction: Small bowel neuroendocrine tumours (sb-NETs) and related mesenteric tumour deposits (MTDs) can present dense collagen and fibrosis. Despite well-known clinical consequences of this characteristic (bowel obstruction and ischemia), the relationship between SB-NETs and MTDs collagen deposition has been poorly evaluated.

Conference:

Presenting Author: Ali M

Authors: Ali M, Gambella A, Checchin F, Malerba D, Sambuceti V,

Keywords: neuroendocrine tumour, small intestine, collagen, fibrosis,

#4474 Follow-up 68Ga-DOTATATE PET/CT post resection of small bowel neuroendocrine neoplasia

Introduction: Surgery remains the mainstay of treatment for resectable neuroendocrine neoplasms (NENs). Post resection, guidelines suggest a risk-based approach to surveillance, with 3-6 monthly imaging based on tumour biology. However, there is a paucity of data regarding the timing of surveillance imaging for resected well-differentiated NEN.

Conference:

Presenting Author:

Authors: Sabahi Z, Chan D, Darbhamulla S, Mok C, Samra J,

Keywords: Neuroendocrine, 68Ga-DOTATATE PET/CT, Small bowel,

#4402 Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET: A randomised study of cessation of somatostatin analogues after peptide receptor radionuclide therapy (PRRT) in mid, hind-gut, and pancreatic neuroendocrine tumours

Introduction: After progressing on somatostatin analogues (SSA), patients with somatostatin receptor positive gastroenteropancreatic (GEP) NETs often receive PRRT. It is unclear whether current practice of continuing SSA after commencing PRRT is beneficial, especially in non-functioning NETs.

Conference:

Presenting Author:

Authors: Burge M, Wyld D, Pattison D, Loree J, Goodwin R,

Keywords: Somatostatin analogue, peptide receptor radionuclide therapy, gastroenteropancreatic, neuroendocrine, non-functioning, cessation, Australasian Gastro-Intestinal Trials Group (AGITG), Canadian Cancer Trials Group (CCTG),

#4357 Proof of concept and design of an externally controlled trial for patients with gastroenteropancreatic neuroendocrine carcinomas based on the randomised phase II BEVANEC trial

Introduction: Neuroendocrine carcinomas of digestive or unknown primary trials are challenging to perform because of disease rarity. BEVANEC trial randomised 126 patients to FOLFIRI +/- bevacizumab in second line, over 5 years, and reported similar overall survival (OS) in both arms.

Conference:

Presenting Author: Hadoux J

Authors: Ganame S, Walter T, Durand A, Lièvre A, Tougeron D,

Keywords: Neuroendocrine carcinoma, synthetic control arm, external control arm, new clinical trial design, randomisation algorithm, real-world data, invers probability weighting,